← Leaderboards
Wendell G Yarbrough
University Of North Carolina Chapel Hill
$10,193,706
Attributed
$15,000,722
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,000,722 · 10
By mechanism
R01$8,527,956 · 3
U01$3,752,383 · 1
RC1$1,415,404 · 2
R21$759,191 · 2
R56$370,167 · 1
K08$175,621 · 1
Top collaborators
- Natalia Issaeva13 shared
- Karen S Anderson5 shared
- Daniel Ma3 shared
- Kathryn Van Abel3 shared
- Bhisham Chera1 shared
- Gaorav P. Gupta1 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Norman Edward Sharpless$12,085,254
- Yanping Zhang$10,224,049
- Winston C Patterson$23,185,986
- Valerie A Murrah$72,750
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsCharacteristicsRadiationOncogenicCellsClinical TrialsTumor Suppressor ProteinsApoptosisHead And Neck Squamous Cell CarcinomaTumorigenesisIncidenceLeadValidationGenesChemotherapyTumor GrowthPreventGrowthMolecularPrognostic MarkerGene ExpressionHuman PapillomavirusCervical And Uterine Cancer
Grant awards (39)
Dissecting NF-kB pathway in HPV-associated head and neck cancer$509,676
R01 · FY2025 · DE · contact PI
Observational study to validate circulating HPVDNA and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated OPSCC$704,533
U01 · FY2024 · DE · contact PI
Dissecting NF-kB pathway in HPV-associated head and neck cancer$536,605
R01 · FY2024 · DE · contact PI
Observational study to validate circulating HPVDNA and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated OPSCC$735,619
U01 · FY2023 · DE · contact PI
Dissecting NF-kB pathway in HPV-associated head and neck cancer$488,746
R01 · FY2023 · DE · contact PI
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer$404,678
R01 · FY2023 · DE · contact PI
Observational study to validate circulating HPVDNA and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated OPSCC$741,313
U01 · FY2022 · DE · contact PI
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer$400,632
R01 · FY2022 · DE · contact PI
Observational study to validate circulating HPVDNA and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated OPSCC$761,468
U01 · FY2021 · DE · contact PI
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer$404,678
R01 · FY2021 · DE · contact PI
Observational study to validate circulating HPVDNA and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated OPSCC$809,450
U01 · FY2020 · DE · contact PI
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer$404,678
R01 · FY2020 · DE · contact PI
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer$487,357
R01 · FY2019 · DE · contact PI
Tumor Suppressor Qualities and Mechanisms of LZAP Activity$416,250
R01 · FY2016 · DE · contact PI
Tumor Suppressor Qualities and Mechanisms of LZAP Activity$416,250
R01 · FY2015 · DE · contact PI
Tumor Suppressor Qualities and Mechanisms of LZAP Activity$416,250
R01 · FY2014 · DE · contact PI
Validated Modeling and Culture of Salivary Cancers$249,750
R21 · FY2014 · DE · contact PI
Tumor Suppressor Qualities and Mechanisms of LZAP Activity$398,899
R01 · FY2013 · DE · contact PI
Validated Modeling and Culture of Salivary Cancers$207,604
R21 · FY2013 · DE · contact PI
Tumor Suppressor Qualities and Mechanisms of LZAP Activity$301,256
R01 · FY2012 · DE · contact PI
Tumor Suppressor Qualities and Mechanisms of LZAP Activity$94,432
R01 · FY2012 · DE · contact PI
Human in Mouse Modeling of HNSCC to Predict Resonse to Therapy$377,139
RC1 · FY2010 · CA · contact PI
Tumor suppressor qualities and mechanisms of LZAP activity$370,167
R56 · FY2010 · DE · contact PI
Development and Profiling of Human-in-Mouse Models of Salivary Carcinomas$311,763
RC1 · FY2010 · DE · contact PI
Human in Mouse Modeling of HNSCC to Predict Resonse to Therapy$397,820
RC1 · FY2009 · CA · contact PI
NOVEL PROTEIN REGULATOR OF TUMOR SUPPRESSOR ARF & NF-kB$359,862
R01 · FY2009 · DE · contact PI
Development and Profiling of Human-in-Mouse Models of Salivary Carcinomas$328,682
RC1 · FY2009 · DE · contact PI
NOVEL PROTEIN REGULATOR OF TUMOR SUPPRESSOR ARF & NF-kB$359,862
R01 · FY2008 · DE · contact PI
NOVEL PROTEIN REGULATOR OF TUMOR SUPPRESSOR ARF & NF-kB$363,666
R01 · FY2007 · DE · contact PI
NOVEL PROTEIN REGULATOR OF TUMOR SUPPRESSOR ARF & NF-kB$373,105
R01 · FY2006 · DE · contact PI
NOVEL PROTEIN REGULATOR OF TUMOR SUPPRESSOR ARF &NF-kB$380,000
R01 · FY2005 · DE
Gene Expression as Predictor of Metastasis in HNSCC$150,837
R21 · FY2004 · CA
ARF AS A THERAPEUTIC AGENT IN ORAL MALIGNANCIES$256,700
R01 · FY2003 · DE
Gene Expression as Predictor of Metastasis in HNSCC$151,000
R21 · FY2003 · CA
ARF AS A THERAPEUTIC AGENT IN ORAL MALIGNANCIES$243,946
R01 · FY2002 · DE
ARF AS A THERAPEUTIC AGENT IN ORAL MALIGNANCIES$243,946
R01 · FY2001 · DE
P16 IN HEAD AND NECK SQUAMOUS CELL CARCINOGENESIS$87,991
K08 · FY2001 · CA
ARF AS A THERAPEUTIC AGENT IN ORAL MALIGNANCIES$266,482
R01 · FY2000 · DE
P16 IN HEAD AND NECK SQUAMOUS CELL CARCINOGENESIS$87,630
K08 · FY2000 · CA